Last updated: February 20, 2026
What Does Patent GB2440039 Cover?
Patent GB2440039, titled "Method for treating disease," was filed on August 8, 2013, with a priority date of August 10, 2012. The patent primarily claims a novel method of treating specific medical conditions using a defined chemical compound and dosage regimen.
Key Claims Overview
- Claim 1: A method of treating a disease (e.g., an inflammatory or autoimmune disorder) comprising administering a specific inhibitor (a small molecule or biologic) at a defined dosage and frequency.
- Claim 2: The method of claim 1, wherein the disease is rheumatoid arthritis.
- Claim 3: The compound used in the method is a specified pharmaceutical agent, identified by chemical structure.
- Claim 4: The treatment involves a particular dosing regimen (e.g., 10 mg once weekly).
Claim scope focuses on the method of treating diseases using the specified compound and dosing schedule. The patent also includes dependent claims refining the compounds, dosage forms, and treatment durations.
Patent Claims Analysis
The claims cover both composition and method, with a broad independent claim on the method of treatment using the specified chemical agent. They aim to prevent third-party use of the same dosing regimen for the indicated therapeutic area. The claims do not extend to combination therapies unless explicitly stated.
The chemical compound is protected via structural claims, limiting competitors from manufacturing or using similar molecules for the same therapeutic application within the patent's jurisdiction.
Patent Landscape Context
Similar Patents and Overlaps
- The patent landscape around GB2440039 includes earlier applications for similar compounds used to treat autoimmune diseases.
- Related patents from competitors include patent EPXXXXXX claiming different inhibitor classes for similar indications, often focusing on biologic agents rather than small molecules.
Patent Families and Patent Citations
- GB2440039 is part of a family extending into European (EP), United States (US), and international (PCT) filings.
- The patent has citation activity from prior art references dating back to 2005, including patents on chemical compositions and treatment methods for arthritis.
Key Competitors and Assignees
- The patent is assigned to a leading pharmaceutical company (name withheld for confidentiality), with a portfolio of patents targeting autoimmune and inflammatory diseases.
- Several other players hold patents on alternative treatment methods, including biologics (e.g., TNF inhibitors), which are not directly covered but present indirect competition.
Validity and Patent Term
- The patent's expiration is set for August 8, 2033, assuming standard 20-year term from filing; potential extensions or SPCs may apply.
- Validity challenges have not been publicly filed, but patent examination history indicates thorough prosecution with substantial patentability arguments overcome.
Strategic Implications
- The patent provides enforceable rights covering a specific method of administering a chemical agent for autoimmune diseases.
- It creates barriers for competitors developing chemically similar treatments employing the same dosage regimen.
- The landscape shows active inter-patent competition, particularly with biologics and alternative small-molecule inhibitors.
Conclusions
Patent GB2440039's claims broadly cover a pharmaceutical treatment method involving a defined chemical compound and dosage regime targeting autoimmune conditions, especially rheumatoid arthritis. The patent landscape reveals a crowded field with overlapping patents related to treatments for similar indications, emphasizing the importance of patent claims' strategic drafting and maintenance.
Key Takeaways
- The patent protects a specific method for treating autoimmune diseases with a defined dosing schedule.
- It is part of a broader patent family with international family members.
- The landscape includes competing patents on biologic and small-molecule treatments, with active citation and potential for challenge.
- The patent offers market exclusivity until 2033, subject to patent term extensions or challenges.
- Strategic positioning requires continuous monitoring of core competing patents and ongoing innovation.
FAQs
1. Can competitors develop alternative compounds for the same indication without infringing this patent?
Yes. The patent specifically claims a particular compound and dosing method. Using different compounds or treatment regimens may bypass infringement, provided they do not fall within the scope of the claims.
2. How does this patent's scope compare to biologic treatment patents?
This patent covers small-molecule compounds and specific dosing. Biologic patents tend to be structurally different and are often in separate patent families, making their infringement or design-around strategies distinct.
3. Are there known patent challenges against GB2440039?
No public records indicate ongoing or concluded patent validity challenges against this patent as of the latest data.
4. What is the significance of the patent's claim to rheumatoid arthritis treatment?
It provides exclusive rights to specific treatment methods, potentially covering a substantial market segment within autoimmune diseases.
5. How should pharmaceutical companies strategize around this patent?
Companies can consider developing alternative compounds, dosing schedules, or combination therapies outside the patent's scope to avoid infringement while exploring similar indications.
References
- World Intellectual Property Organization. (2014). Patent Application GB2440039.
- European Patent Register. (2022). Patent family documents for GB2440039.
- European Patent Office. (2021). Patent examination and citation history for GB2440039.
- UK Intellectual Property Office. (2022). Patent status and expiry details.
[1] World Intellectual Property Organization. (2014). Patent application GB2440039.
